S&P 500   3,348.23 (+1.51%)
DOW   27,637.68 (+1.71%)
QQQ   274.73 (+1.17%)
AAPL   113.23 (+0.85%)
MSFT   208.80 (+0.47%)
FB   256.29 (+0.58%)
GOOGL   1,449.16 (+0.70%)
AMZN   3,145.60 (+1.63%)
TSLA   419.34 (+2.95%)
NVDA   513.88 (-0.21%)
BABA   275.97 (+1.80%)
CGC   14.05 (-0.85%)
GE   6.26 (+2.45%)
MU   49.45 (+0.63%)
AMD   78.73 (+0.86%)
T   28.33 (+1.03%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.86 (+0.98%)
NFLX   481.90 (-0.20%)
DIS   125.85 (+1.49%)
BAC   24.15 (+2.81%)
BA   165.23 (+5.90%)
S&P 500   3,348.23 (+1.51%)
DOW   27,637.68 (+1.71%)
QQQ   274.73 (+1.17%)
AAPL   113.23 (+0.85%)
MSFT   208.80 (+0.47%)
FB   256.29 (+0.58%)
GOOGL   1,449.16 (+0.70%)
AMZN   3,145.60 (+1.63%)
TSLA   419.34 (+2.95%)
NVDA   513.88 (-0.21%)
BABA   275.97 (+1.80%)
CGC   14.05 (-0.85%)
GE   6.26 (+2.45%)
MU   49.45 (+0.63%)
AMD   78.73 (+0.86%)
T   28.33 (+1.03%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.86 (+0.98%)
NFLX   481.90 (-0.20%)
DIS   125.85 (+1.49%)
BAC   24.15 (+2.81%)
BA   165.23 (+5.90%)
S&P 500   3,348.23 (+1.51%)
DOW   27,637.68 (+1.71%)
QQQ   274.73 (+1.17%)
AAPL   113.23 (+0.85%)
MSFT   208.80 (+0.47%)
FB   256.29 (+0.58%)
GOOGL   1,449.16 (+0.70%)
AMZN   3,145.60 (+1.63%)
TSLA   419.34 (+2.95%)
NVDA   513.88 (-0.21%)
BABA   275.97 (+1.80%)
CGC   14.05 (-0.85%)
GE   6.26 (+2.45%)
MU   49.45 (+0.63%)
AMD   78.73 (+0.86%)
T   28.33 (+1.03%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.86 (+0.98%)
NFLX   481.90 (-0.20%)
DIS   125.85 (+1.49%)
BAC   24.15 (+2.81%)
BA   165.23 (+5.90%)
S&P 500   3,348.23 (+1.51%)
DOW   27,637.68 (+1.71%)
QQQ   274.73 (+1.17%)
AAPL   113.23 (+0.85%)
MSFT   208.80 (+0.47%)
FB   256.29 (+0.58%)
GOOGL   1,449.16 (+0.70%)
AMZN   3,145.60 (+1.63%)
TSLA   419.34 (+2.95%)
NVDA   513.88 (-0.21%)
BABA   275.97 (+1.80%)
CGC   14.05 (-0.85%)
GE   6.26 (+2.45%)
MU   49.45 (+0.63%)
AMD   78.73 (+0.86%)
T   28.33 (+1.03%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.86 (+0.98%)
NFLX   481.90 (-0.20%)
DIS   125.85 (+1.49%)
BAC   24.15 (+2.81%)
BA   165.23 (+5.90%)
Log in
FRA:MRK

Merck KGaA Stock Forecast, Price & News

€124.00
+0.30 (+0.24 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
€121.90
Now: €124.00▼
€124.00
50-Day Range
€111.55
MA: €117.14▼
€126.75
52-Week Range
€76.60
Now: €124.00▼
€115.00
Volume368,605 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Read More
Merck KGaA logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.87 out of 5 stars


Industry, Sector and Symbol

Stock Exchange FRA
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolFRA:MRK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.merckgroup.com
Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees51,039
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableOptionable
€124.00
+0.30 (+0.24 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merck KGaA (FRA:MRK) Frequently Asked Questions

How has Merck KGaA's stock price been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at €98.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRK shares have increased by 25.7% and is now trading at €124.00.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Merck KGaA?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Merck KGaA.

What price target have analysts set for MRK?

14 brokers have issued twelve-month price objectives for Merck KGaA's shares. Their forecasts range from €92.00 to €140.00. On average, they anticipate Merck KGaA's share price to reach €116.08 in the next year. This suggests that the stock has a possible downside of 6.4%.
View analysts' price targets for Merck KGaA.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Althea Group (AGH), Applied Biosciences (APPB), Auscann Group (AC8), Ayr Strategies (AYRSF), Biome Grow (BIO), Blueberries Medical (BBM), Canbiola (CANB), Cannara Biotech (LOVE), Cannpal Animal Therapeutics (CP1), Cansortium (CNTMF) and Charlotte's Web (CWBHF).
View all competitors.

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include Micron Technology (MU), NVIDIA (NVDA), QUALCOMM (QCOM), Abbott Laboratories (ABT), Cisco Systems (CSCO), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Boeing (BA), CVS Health (CVS) and Eli Lilly And Co (LLY).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
  • Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
  • Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
  • Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €124.00.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.

This page was last updated on 9/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.